This summer, Mitacs Globalink intern Anton Gladyr, an undergraduate student from Ukraine, is working under the guidance of Professor John Kildea to expand the app’s functionality. Anton is developing a user-friendly interface that will collect data from patients as they undergo treatment.
In collaboration with University of Waterloo-Mitacs researcher, Yael Zilberman-Simakov, LeNano's portable device tests blood for a specific biomarker, a type of protein, elevated by the onset of heart failure. “If a patient has a higher-than-usual concentration of the biomarker, they are at an increased risk of having heart failure,” says Yael. “Similar to how glucose levels should be monitored among diabetic patients, this type of protein needs to be checked every day.Compared to a lab test, personal test devices like LeNano's are faster, simpler, and more convenient.
The company is a spin-off from McMaster University and was created “organically,” says InnovoGENE CEO Kha Tram. It all started when Kha was completing his PhD at McMaster and was looking to develop technology that could quickly identify E. coli in food. He realized the same technology could be used to rapidly test bacteria in water — and InnovoGENE was born.
With the help of his Dalhousie Accelerate supervisors, Professor David Roach from the Rowe School of Business, and Professor Jan Haelssig from the Faculty of Engineering, Hamed has started a company to develop technology that will make continuous positive airway pressure (CPAP) therapy more comfortable for patients.
Ottawa’s branch of the Canadian Mental Health Association (CMHA), in partnership with the Champlain Local Health Integration Network, has launched a unique program called “Familiar Faces” to overcome this problem.
Since 2014, the initiative has increased communication between hospitals and community-based mental health organizations to identify the ER’s familiar faces, pinpoint where they need more support, and direct them to agencies that can help. In partnership with Mitacs Accelerate, the project has been able to take another important step: research and evaluation.
From there, new protocols for screening and handling blood products were enacted to prevent the spread of these diseases through blood donation programs.
Over 30 years later, infectious diseases such as Zika and West Nile virus pose new challenges for the safety of blood donation around the world; however, a partnership between a multidisciplinary team of researchers at Université Laval, Quebec-based Phytronix, and international biotechnology firm Waters Corporation could revolutionize screening technology for donated blood products.
Electricity, water supplies, communication networks, and public transportation were totally shut down. When her parents were unable to get home, Ashwini knew she wanted to do something to better warn people.
This summer, Ashwini has travelled to Canada through the Mitacs Globalink program to do research with Dr. Jennifer He at the University of Calgary’s Schulich School of Engineering. Their research focuses on using weather forecasts to predict extreme events such as floods and develop suitable warning times.
Thousands of kilometers away in Halifax, Canada, Mitacs Globalink intern Lisandra Oliviera is working with a team of researchers at the IWK Health Centre to conduct a systematic review of intervention therapies for parents of children with disabilities similar to microcephaly – a family of conditions known as neurodevelopmental disorders. The parenting intervention includes an “orientation” for family members to develop their parenting skills in ways that will help with management of symptoms and improved mental health for the children.
Thanks to a Mitacs Accelerate partnership with industry, researchers have discovered how a type of dietary fat can provide relief for this disease, and create business opportunities for the treatment of other conditions.
John Miklavcic was working on his PhD at the university’s Alberta Institute for Human Nutrition when he began an Accelerate internship with Biolipids Inc. The goal was to look into whether gangliosides — special kinds of dietary fat that help prevent infection and regulate the immune system — could be used to treat IBD.